A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)

Noura Radwan1, Ryan Phillips1, Ashley Ross2,3, Steven P. Rowe4, Michael A. Gorin3, Emmanuel S. Antonarakis2, Curtiland Deville1,2, Stephen Greco1, Samuel Denmeade2,3, Channing Paller2, Daniel Y. Song1,2,3, Maximilian Diehn5, Hao Wang2, Michael Carducci2,3, Kenneth J. Pienta2,3, Martin G. Pomper1,2,3,4, Theodore L. DeWeese1,2,3, Adam Dicker6, Mario Eisenberger2,3 and Phuoc T. Tran1,2,3 1Department of Radiation Oncology & Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB2 Rm 406, Baltimore, MD 21231, USA. 2Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5Department of Radiation Oncology, Stanford University, Stanford, CA, USA. 6Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.